查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1472342

全球肾上腺素市场：依产品类型、应用、通路：机会分析与产业预测（2023-2032）

Epinephrine Market By Product Type, By Application, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2023-2032
出版日期: | 出版商: Allied Market Research | 英文 266 Pages | 商品交期: 2-3个工作天内

价格

2022年全球肾上腺素市场规模为26亿美元，预计2032年将达44亿美元，2023年至2032年复合年增长率为5.6%。

肾上腺素，也称为肾上腺素，是一种荷尔蒙和神经传导物质，在身体对压力和危险的反应中发挥重要作用。它是在位于肾臟顶部的肾上腺中产生的。肾上腺素会因各种刺激（包括恐惧、压力和兴奋）而释放到血液中。一旦释放，肾上腺素会引发一系列生理反应，旨在让身体做好行动准备。这些反应包括增加心率、增加血压、扩张肺部气道以提高摄氧量以及将血流重新引导至肌肉。肾上腺素还可以提高警觉性和意识，帮助您对任务快速做出反应。

肾上腺素市场-IMG1

例如，它可用于治疗过敏反应（严重过敏反应）、心臟麻痹、支气管痉挛和其他心律不整。患者透过注射、吸入或鼻喷剂服用肾上腺素。因此，它可以透过空气流入和能量可用性等机制来提高血液循环速度，为剧烈的体力消耗或感知到的威胁做好准备。

肾上腺素市场受到过敏反应、气喘和食物过敏等过敏性疾病发生率增加的推动。这些可能会引起强烈且可能致命的反应，需要使用肾上腺素作为第一线治疗。例如，根据美国过敏、气喘和免疫学院 (ACAAI) 的数据，截至 2021 年，美国约有 2,000 万人有食物过敏。过敏反应是一种严重的、有时致命的过敏反应，当患有灾难性食物过敏的人意外接触食物过敏原时，会导致呼吸困难、喉咙肿胀和血压突然下降。在这些情况下，及时服用肾上腺素对于解决危险症状至关重要，这推动了对肾上腺素的需求。

此外，紧急医疗服务（EMS）的成长也有助于推动产业内的肾上腺素需求。处理各种危及生命的病例（例如心臟麻痹和过敏反应）的初期应变人员通常会服用这种药物，因此成为其紧急医疗套件的一部分。紧急医疗服务的可用性和可近性的改善以及对紧急医疗护理的需求的增加极大地促进了肾上腺素需求的成长。

此外，人口老化也是肾上腺素市场成长的因素。随着年龄的增长，我们更容易出现过敏反应和慢性呼吸道疾病，例如气喘和慢性阻塞性肺病（COPD）。在这种情况下，肾上腺素有时被用作救命药物，以控制严重症状并预防併发症，从而支持市场成长。

然而，肾上腺素产品的监管挑战和严格的核准流程可能会限制市场成长。为了确保肾上腺素製剂的安全性和有效性，监管机构经常对製造、标籤和分销施加严格的标准，这可能会延迟产品上市，增加製造商的成本，并对市场成长产生负面影响。相较之下，药物输送系统的技术进步，例如开发更易于使用且更方便的肾上腺素自动注射器，提高了患者的依从性和市场渗透率。配方技术、包装设计、设备易用性等方面的创新预计将为预测期内的市场成长创造利润丰厚的机会。

肾上腺素市场按产品类型、应用、分销管道和地区细分。依产品类型划分，市场分为自动注射器、预填充式注射器等。根据应用，市场分为过敏反应、心臟麻痹等。依销售管道分为院内药局、药局/零售药局、网路药局。依地区划分，北美（美国、加拿大、墨西哥）、欧洲（德国、法国、英国、义大利、西班牙、其他欧洲国家）、亚太地区（日本、中国、澳洲、印度、韩国、其他亚太地区）、拉丁美洲（分析分为三个区域：巴西、哥伦比亚、阿根廷、其他拉丁美洲）、中东/非洲（海合会国家、南非、北非、其他中东/非洲）。

相关人员的主要利益

本报告定量分析了 2022 年至 2032 年肾上腺素市场分析的细分市场、当前趋势、估计/趋势和动态，以确定当前的肾上腺素市场机会。

我们提供市场研究以及与市场驱动因素、市场限制和市场机会相关的资讯。

波特的五力分析强调买家和供应商帮助相关人员做出利润驱动的商业决策并加强供应商-买家网路的潜力。

肾上腺素市场细分的详细分析将有助于确定市场机会。

每个地区的主要国家都根据其对全球市场的收益贡献绘製了地图。

市场公司定位有助于基准化分析并提供对市场公司当前地位的清晰了解。

该报告包括对区域和全球肾上腺素市场趋势、主要企业、细分市场、应用领域和市场成长策略的分析。

可以使用此报告进行报告客製化（请联络销售人员以了解额外费用和时间表）

  • 监管指引
  • 根据客户兴趣加入公司简介
  • 按国家或地区进行的附加分析：市场规模和预测
  • 公司简介的扩充列表
  • 历史市场资料
  • 主要企业详细资料（Excel 格式，包括位置、联络资讯、供应商/供应商网路等）

目录

第一章简介

第 2 章执行摘要

第三章市场概况

  • 市场定义和范围
  • 主要发现
    • 影响因素
    • 主要投资机会
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章肾上腺素市场：依产品类型

  • 概述
  • 自动注射器
  • 预填充式注射器
  • 其他的

第五章肾上腺素市场：依应用分类

  • 概述
  • 过敏反应
  • 心臟麻痹
  • 其他的

第六章 肾上腺素市场：依通路

  • 概述
  • 院内药房
  • 药局/零售药房
  • 线上提供者

第七章 肾上腺素市场：依地区

  • 概述
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 韩国
    • 其他的
  • 拉丁美洲
    • 巴西
    • 哥伦比亚
    • 阿根廷
    • 其他的
  • 中东/非洲
    • 海湾合作委员会国家
    • 南非
    • 北非
    • 其他的

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2022年）

第九章 公司简介

  • Adamis Pharmaceuticals Corporation
  • AdvaCare Pharma
  • ALK
  • Amneal Pharmaceuticals LLC.
  • Amphastar Pharmaceuticals, Inc.
  • Grand Pharma（China）Co., Ltd.
  • kaleo, Inc.
  • Pfizer
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
Product Code: A65539

The epinephrine market was valued at $2.6 billion in 2022 and is projected to reach $4.4 billion by 2032, registering a CAGR of 5.6% from 2023 to 2032. Epinephrine, also known as adrenaline, is a hormone and neurotransmitter that plays a vital role in the body's response to stress or danger. It is produced by the adrenal glands, located on top of the kidneys. Epinephrine is released into the bloodstream in response to various stimuli, such as fear, stress, or excitement. Once released, epinephrine triggers a series of physiological responses aimed at preparing the body for action. These responses include increased heart rate, elevated blood pressure, dilation of the airways in the lungs to improve oxygen intake, and redirection of blood flow to the muscles. Epinephrine also enhances alertness and awareness, helping individuals react quickly to challenging situations.

Epinephrine Market - IMG1

It can be used medicinally, for instance, during ana-phylaxis (severe allergic reactions), cardiac arrest, bronchospasm, or other arrhythmias. Patients take epinephrine by injection inhalers or even nasal sprays; thus, the result helps them get ready for intense physical exertions and/or perceived threats by increase in circulation rates of blood through such mechanisms as air entry and energy availability, among others.

The epinephrine market is driven by the increase in incidence of allergic conditions such as anaphylaxis, asthma, and food allergies. These in turn can provoke strong and potentially lethal reactions that can require epinephrine use as a first line treatment. For instance, according to the American College of Allergy, Asthma, and Immunology (ACAAI), as of 2021, about 20 million people had food allergies in the U.S. Anaphylaxis is a severe and sometimes fatal allergic response that causes breathing problems, throat swelling or a sudden fall in blood pressure if people with devastating food allergies are accidentally exposed to them. In these cases, quick administration of epinephrine is essential to counteract dangerous symptoms, which drives the demand for epinephrine.

In addition, the growth of emergency medical services (EMS) has also been instrumental in propelling the demand for epinephrine within the industry. Paramedics and first responders who attend various life-threatening cases such as cardiac arrest and anaphylaxis among others, are usually given this medicine and thus, it forms a part of their emergency medical kits. The increased availability and accessibility of emergency medical services coupled with rise in demand for emergency care have been key contributors to growth in demand for epinephrine.

Furthermore, the aging population is another factor contributing to the growth of the epinephrine market. As people age, they become more susceptible to allergic reactions and chronic respiratory conditions, such as asthma and chronic obstructive pulmonary disease (COPD). In these cases, epinephrine may be prescribed as a life-saving medication to manage severe symptoms and prevent complications, which supports the market growth.

However, the regulatory challenges and stringent approval processes for epinephrine products can limit market growth. Regulatory agencies often impose rigorous standards for the manufacturing, labeling, and distribution of epinephrine medications to ensure their safety and efficacy lead to delays in product launches and increased costs for manufacturers, which negatively impacted the market growth. In contrast, technological advancements in drug delivery systems, such as the development of more user-friendly and convenient epinephrine auto-injectors, enhance patient compliance and market penetration. Such innovations in formulation techniques, packaging designs, and device usability are expected to create lucrative opportunities for market growth during the forecast period.

The epinephrine market is segmented on the basis of product type, application, distribution channel, and region. By product type, the market is classified into auto-injector, prefilled syringe, and others. By application, the market is divided into anaphylaxis, cardiac arrest, and others. By distribution channel, it is segregated into hospital pharmacy, drug stores and retail pharmacy, and online pharmacy. Region-wise, the market is analyzed across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), LA (Brazil, Colombia, Argentina, and rest of LA), and MEA (GCC, South Africa, North Africa, and rest of MEA).

Major key players that operate in the epinephrine market are Adamis Pharmaceuticals Corporation, AdvaCare Pharma, ALK-Abello A/S, Amneal Pharmaceuticals LLC., Amphastar Pharmaceuticals, Inc., Antares Pharma, kaleo, Inc., Pfizer, Teva Pharmaceutical Industries Ltd., and Viatris Inc. Key players have adopted agreement and product approval as key developmental strategies to improve the product portfolio of the epinephrine market.

Key Benefits for Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the epinephrine market analysis from 2022 to 2032 to identify the prevailing epinephrine market opportunities.

The market research is offered along with information related to key drivers, restraints, and opportunities.

Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.

In-depth analysis of the epinephrine market segmentation assists to determine the prevailing market opportunities.

Major countries in each region are mapped according to their revenue contribution to the global market.

Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.

The report includes the analysis of the regional as well as global epinephrine market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Historic market data
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

  • Auto-Injector
  • Prefilled Syringe
  • Others

By Application

  • Anaphylaxis
  • Cardiac Arrest
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Drug Stores and Retail Pharmacies
  • Online Providers

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Colombia
    • Argentina
    • Rest Of La
  • Middle East and Africa
    • Gcc
    • South Africa
    • North Africa
    • Rest Of Mea

Key Market Players:

    • Adamis Pharmaceuticals Corporation
    • AdvaCare Pharma
    • ALK
    • Amneal Pharmaceuticals LLC.
    • Amphastar Pharmaceuticals, Inc.
    • Grand Pharma (China) Co., Ltd.
    • kaleo, Inc.
    • Pfizer
    • Teva Pharmaceutical Industries Ltd.
    • Viatris Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report description
  • 1.2. Key market segments
  • 1.3. Key benefits to the stakeholders
  • 1.4. Research methodology
    • 1.4.1. Primary research
    • 1.4.2. Secondary research
    • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

  • 3.1. Market definition and scope
  • 3.2. Key findings
    • 3.2.1. Top impacting factors
    • 3.2.2. Top investment pockets
  • 3.3. Porter's five forces analysis
  • 3.4. Market dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: EPINEPHRINE MARKET, BY PRODUCT TYPE

  • 4.1. Overview
    • 4.1.1. Market size and forecast
  • 4.2. Auto-Injector
    • 4.2.1. Key market trends, growth factors and opportunities
    • 4.2.2. Market size and forecast, by region
    • 4.2.3. Market share analysis by country
  • 4.3. Prefilled Syringe
    • 4.3.1. Key market trends, growth factors and opportunities
    • 4.3.2. Market size and forecast, by region
    • 4.3.3. Market share analysis by country
  • 4.4. Others
    • 4.4.1. Key market trends, growth factors and opportunities
    • 4.4.2. Market size and forecast, by region
    • 4.4.3. Market share analysis by country

CHAPTER 5: EPINEPHRINE MARKET, BY APPLICATION

  • 5.1. Overview
    • 5.1.1. Market size and forecast
  • 5.2. Anaphylaxis
    • 5.2.1. Key market trends, growth factors and opportunities
    • 5.2.2. Market size and forecast, by region
    • 5.2.3. Market share analysis by country
  • 5.3. Cardiac Arrest
    • 5.3.1. Key market trends, growth factors and opportunities
    • 5.3.2. Market size and forecast, by region
    • 5.3.3. Market share analysis by country
  • 5.4. Others
    • 5.4.1. Key market trends, growth factors and opportunities
    • 5.4.2. Market size and forecast, by region
    • 5.4.3. Market share analysis by country

CHAPTER 6: EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Overview
    • 6.1.1. Market size and forecast
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key market trends, growth factors and opportunities
    • 6.2.2. Market size and forecast, by region
    • 6.2.3. Market share analysis by country
  • 6.3. Drug Stores and Retail Pharmacies
    • 6.3.1. Key market trends, growth factors and opportunities
    • 6.3.2. Market size and forecast, by region
    • 6.3.3. Market share analysis by country
  • 6.4. Online Providers
    • 6.4.1. Key market trends, growth factors and opportunities
    • 6.4.2. Market size and forecast, by region
    • 6.4.3. Market share analysis by country

CHAPTER 7: EPINEPHRINE MARKET, BY REGION

  • 7.1. Overview
    • 7.1.1. Market size and forecast By Region
  • 7.2. North America
    • 7.2.1. Key market trends, growth factors and opportunities
    • 7.2.2. Market size and forecast, by Product Type
    • 7.2.3. Market size and forecast, by Application
    • 7.2.4. Market size and forecast, by Distribution Channel
    • 7.2.5. Market size and forecast, by country
      • 7.2.5.1. U.S.
      • 7.2.5.1.1. Market size and forecast, by Product Type
      • 7.2.5.1.2. Market size and forecast, by Application
      • 7.2.5.1.3. Market size and forecast, by Distribution Channel
      • 7.2.5.2. Canada
      • 7.2.5.2.1. Market size and forecast, by Product Type
      • 7.2.5.2.2. Market size and forecast, by Application
      • 7.2.5.2.3. Market size and forecast, by Distribution Channel
      • 7.2.5.3. Mexico
      • 7.2.5.3.1. Market size and forecast, by Product Type
      • 7.2.5.3.2. Market size and forecast, by Application
      • 7.2.5.3.3. Market size and forecast, by Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key market trends, growth factors and opportunities
    • 7.3.2. Market size and forecast, by Product Type
    • 7.3.3. Market size and forecast, by Application
    • 7.3.4. Market size and forecast, by Distribution Channel
    • 7.3.5. Market size and forecast, by country
      • 7.3.5.1. Germany
      • 7.3.5.1.1. Market size and forecast, by Product Type
      • 7.3.5.1.2. Market size and forecast, by Application
      • 7.3.5.1.3. Market size and forecast, by Distribution Channel
      • 7.3.5.2. France
      • 7.3.5.2.1. Market size and forecast, by Product Type
      • 7.3.5.2.2. Market size and forecast, by Application
      • 7.3.5.2.3. Market size and forecast, by Distribution Channel
      • 7.3.5.3. UK
      • 7.3.5.3.1. Market size and forecast, by Product Type
      • 7.3.5.3.2. Market size and forecast, by Application
      • 7.3.5.3.3. Market size and forecast, by Distribution Channel
      • 7.3.5.4. Italy
      • 7.3.5.4.1. Market size and forecast, by Product Type
      • 7.3.5.4.2. Market size and forecast, by Application
      • 7.3.5.4.3. Market size and forecast, by Distribution Channel
      • 7.3.5.5. Spain
      • 7.3.5.5.1. Market size and forecast, by Product Type
      • 7.3.5.5.2. Market size and forecast, by Application
      • 7.3.5.5.3. Market size and forecast, by Distribution Channel
      • 7.3.5.6. Rest of Europe
      • 7.3.5.6.1. Market size and forecast, by Product Type
      • 7.3.5.6.2. Market size and forecast, by Application
      • 7.3.5.6.3. Market size and forecast, by Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key market trends, growth factors and opportunities
    • 7.4.2. Market size and forecast, by Product Type
    • 7.4.3. Market size and forecast, by Application
    • 7.4.4. Market size and forecast, by Distribution Channel
    • 7.4.5. Market size and forecast, by country
      • 7.4.5.1. Japan
      • 7.4.5.1.1. Market size and forecast, by Product Type
      • 7.4.5.1.2. Market size and forecast, by Application
      • 7.4.5.1.3. Market size and forecast, by Distribution Channel
      • 7.4.5.2. China
      • 7.4.5.2.1. Market size and forecast, by Product Type
      • 7.4.5.2.2. Market size and forecast, by Application
      • 7.4.5.2.3. Market size and forecast, by Distribution Channel
      • 7.4.5.3. India
      • 7.4.5.3.1. Market size and forecast, by Product Type
      • 7.4.5.3.2. Market size and forecast, by Application
      • 7.4.5.3.3. Market size and forecast, by Distribution Channel
      • 7.4.5.4. Australia
      • 7.4.5.4.1. Market size and forecast, by Product Type
      • 7.4.5.4.2. Market size and forecast, by Application
      • 7.4.5.4.3. Market size and forecast, by Distribution Channel
      • 7.4.5.5. South Korea
      • 7.4.5.5.1. Market size and forecast, by Product Type
      • 7.4.5.5.2. Market size and forecast, by Application
      • 7.4.5.5.3. Market size and forecast, by Distribution Channel
      • 7.4.5.6. Rest of Asia-Pacific
      • 7.4.5.6.1. Market size and forecast, by Product Type
      • 7.4.5.6.2. Market size and forecast, by Application
      • 7.4.5.6.3. Market size and forecast, by Distribution Channel
  • 7.5. Latin America
    • 7.5.1. Key market trends, growth factors and opportunities
    • 7.5.2. Market size and forecast, by Product Type
    • 7.5.3. Market size and forecast, by Application
    • 7.5.4. Market size and forecast, by Distribution Channel
    • 7.5.5. Market size and forecast, by country
      • 7.5.5.1. Brazil
      • 7.5.5.1.1. Market size and forecast, by Product Type
      • 7.5.5.1.2. Market size and forecast, by Application
      • 7.5.5.1.3. Market size and forecast, by Distribution Channel
      • 7.5.5.2. Colombia
      • 7.5.5.2.1. Market size and forecast, by Product Type
      • 7.5.5.2.2. Market size and forecast, by Application
      • 7.5.5.2.3. Market size and forecast, by Distribution Channel
      • 7.5.5.3. Argentina
      • 7.5.5.3.1. Market size and forecast, by Product Type
      • 7.5.5.3.2. Market size and forecast, by Application
      • 7.5.5.3.3. Market size and forecast, by Distribution Channel
      • 7.5.5.4. Rest Of La
      • 7.5.5.4.1. Market size and forecast, by Product Type
      • 7.5.5.4.2. Market size and forecast, by Application
      • 7.5.5.4.3. Market size and forecast, by Distribution Channel
  • 7.6. Middle East and Africa
    • 7.6.1. Key market trends, growth factors and opportunities
    • 7.6.2. Market size and forecast, by Product Type
    • 7.6.3. Market size and forecast, by Application
    • 7.6.4. Market size and forecast, by Distribution Channel
    • 7.6.5. Market size and forecast, by country
      • 7.6.5.1. Gcc
      • 7.6.5.1.1. Market size and forecast, by Product Type
      • 7.6.5.1.2. Market size and forecast, by Application
      • 7.6.5.1.3. Market size and forecast, by Distribution Channel
      • 7.6.5.2. South Africa
      • 7.6.5.2.1. Market size and forecast, by Product Type
      • 7.6.5.2.2. Market size and forecast, by Application
      • 7.6.5.2.3. Market size and forecast, by Distribution Channel
      • 7.6.5.3. North Africa
      • 7.6.5.3.1. Market size and forecast, by Product Type
      • 7.6.5.3.2. Market size and forecast, by Application
      • 7.6.5.3.3. Market size and forecast, by Distribution Channel
      • 7.6.5.4. Rest Of Mea
      • 7.6.5.4.1. Market size and forecast, by Product Type
      • 7.6.5.4.2. Market size and forecast, by Application
      • 7.6.5.4.3. Market size and forecast, by Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product mapping of top 10 player
  • 8.4. Competitive dashboard
  • 8.5. Competitive heatmap
  • 8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

  • 9.1. Adamis Pharmaceuticals Corporation
    • 9.1.1. Company overview
    • 9.1.2. Key executives
    • 9.1.3. Company snapshot
    • 9.1.4. Operating business segments
    • 9.1.5. Product portfolio
    • 9.1.6. Business performance
    • 9.1.7. Key strategic moves and developments
  • 9.2. AdvaCare Pharma
    • 9.2.1. Company overview
    • 9.2.2. Key executives
    • 9.2.3. Company snapshot
    • 9.2.4. Operating business segments
    • 9.2.5. Product portfolio
    • 9.2.6. Business performance
    • 9.2.7. Key strategic moves and developments
  • 9.3. ALK
    • 9.3.1. Company overview
    • 9.3.2. Key executives
    • 9.3.3. Company snapshot
    • 9.3.4. Operating business segments
    • 9.3.5. Product portfolio
    • 9.3.6. Business performance
    • 9.3.7. Key strategic moves and developments
  • 9.4. Amneal Pharmaceuticals LLC.
    • 9.4.1. Company overview
    • 9.4.2. Key executives
    • 9.4.3. Company snapshot
    • 9.4.4. Operating business segments
    • 9.4.5. Product portfolio
    • 9.4.6. Business performance
    • 9.4.7. Key strategic moves and developments
  • 9.5. Amphastar Pharmaceuticals, Inc.
    • 9.5.1. Company overview
    • 9.5.2. Key executives
    • 9.5.3. Company snapshot
    • 9.5.4. Operating business segments
    • 9.5.5. Product portfolio
    • 9.5.6. Business performance
    • 9.5.7. Key strategic moves and developments
  • 9.6. Grand Pharma (China) Co., Ltd.
    • 9.6.1. Company overview
    • 9.6.2. Key executives
    • 9.6.3. Company snapshot
    • 9.6.4. Operating business segments
    • 9.6.5. Product portfolio
    • 9.6.6. Business performance
    • 9.6.7. Key strategic moves and developments
  • 9.7. kaleo, Inc.
    • 9.7.1. Company overview
    • 9.7.2. Key executives
    • 9.7.3. Company snapshot
    • 9.7.4. Operating business segments
    • 9.7.5. Product portfolio
    • 9.7.6. Business performance
    • 9.7.7. Key strategic moves and developments
  • 9.8. Pfizer
    • 9.8.1. Company overview
    • 9.8.2. Key executives
    • 9.8.3. Company snapshot
    • 9.8.4. Operating business segments
    • 9.8.5. Product portfolio
    • 9.8.6. Business performance
    • 9.8.7. Key strategic moves and developments
  • 9.9. Teva Pharmaceutical Industries Ltd.
    • 9.9.1. Company overview
    • 9.9.2. Key executives
    • 9.9.3. Company snapshot
    • 9.9.4. Operating business segments
    • 9.9.5. Product portfolio
    • 9.9.6. Business performance
    • 9.9.7. Key strategic moves and developments
  • 9.10. Viatris Inc.
    • 9.10.1. Company overview
    • 9.10.2. Key executives
    • 9.10.3. Company snapshot
    • 9.10.4. Operating business segments
    • 9.10.5. Product portfolio
    • 9.10.6. Business performance
    • 9.10.7. Key strategic moves and developments

LIST OF TABLES

  • TABLE 01. GLOBAL EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 02. EPINEPHRINE MARKET FOR AUTO-INJECTOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 03. EPINEPHRINE MARKET FOR PREFILLED SYRINGE, BY REGION, 2022-2032 ($MILLION)
  • TABLE 04. EPINEPHRINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 05. GLOBAL EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 06. EPINEPHRINE MARKET FOR ANAPHYLAXIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 07. EPINEPHRINE MARKET FOR CARDIAC ARREST, BY REGION, 2022-2032 ($MILLION)
  • TABLE 08. EPINEPHRINE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 09. GLOBAL EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 10. EPINEPHRINE MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 11. EPINEPHRINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
  • TABLE 12. EPINEPHRINE MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 13. EPINEPHRINE MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 14. NORTH AMERICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. NORTH AMERICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 16. NORTH AMERICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 17. NORTH AMERICA EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 18. U.S. EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 19. U.S. EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 20. U.S. EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 21. CANADA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. CANADA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 23. CANADA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 24. MEXICO EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 25. MEXICO EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 26. MEXICO EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 27. EUROPE EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. EUROPE EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 29. EUROPE EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 30. EUROPE EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 31. GERMANY EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. GERMANY EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 33. GERMANY EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 34. FRANCE EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 35. FRANCE EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 36. FRANCE EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 37. UK EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 38. UK EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 39. UK EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 40. ITALY EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. ITALY EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 42. ITALY EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 43. SPAIN EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 44. SPAIN EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 45. SPAIN EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 46. REST OF EUROPE EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. REST OF EUROPE EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 48. REST OF EUROPE EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 49. ASIA-PACIFIC EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 50. ASIA-PACIFIC EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 51. ASIA-PACIFIC EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 52. ASIA-PACIFIC EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 53. JAPAN EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 54. JAPAN EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 55. JAPAN EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 56. CHINA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 57. CHINA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 58. CHINA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 59. INDIA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. INDIA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 61. INDIA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 62. AUSTRALIA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 63. AUSTRALIA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 64. AUSTRALIA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 65. SOUTH KOREA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. SOUTH KOREA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 67. SOUTH KOREA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 68. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 69. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 70. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 71. LATIN AMERICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 72. LATIN AMERICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 73. LATIN AMERICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 74. LATIN AMERICA EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 75. BRAZIL EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 76. BRAZIL EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 77. BRAZIL EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 78. COLOMBIA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 79. COLOMBIA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 80. COLOMBIA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 81. ARGENTINA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 82. ARGENTINA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 83. ARGENTINA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 84. REST OF LA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 85. REST OF LA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 86. REST OF LA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 87. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 88. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 89. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 90. MIDDLE EAST AND AFRICA EPINEPHRINE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
  • TABLE 91. GCC EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 92. GCC EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 93. GCC EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 94. SOUTH AFRICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 95. SOUTH AFRICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 96. SOUTH AFRICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 97. NORTH AFRICA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 98. NORTH AFRICA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 99. NORTH AFRICA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 100. REST OF MEA EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 101. REST OF MEA EPINEPHRINE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
  • TABLE 102. REST OF MEA EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
  • TABLE 103. ADAMIS PHARMACEUTICALS CORPORATION: KEY EXECUTIVES
  • TABLE 104. ADAMIS PHARMACEUTICALS CORPORATION: COMPANY SNAPSHOT
  • TABLE 105. ADAMIS PHARMACEUTICALS CORPORATION: PRODUCT SEGMENTS
  • TABLE 106. ADAMIS PHARMACEUTICALS CORPORATION: SERVICE SEGMENTS
  • TABLE 107. ADAMIS PHARMACEUTICALS CORPORATION: PRODUCT PORTFOLIO
  • TABLE 108. ADAMIS PHARMACEUTICALS CORPORATION: KEY STRATERGIES
  • TABLE 109. ADVACARE PHARMA: KEY EXECUTIVES
  • TABLE 110. ADVACARE PHARMA: COMPANY SNAPSHOT
  • TABLE 111. ADVACARE PHARMA: PRODUCT SEGMENTS
  • TABLE 112. ADVACARE PHARMA: SERVICE SEGMENTS
  • TABLE 113. ADVACARE PHARMA: PRODUCT PORTFOLIO
  • TABLE 114. ADVACARE PHARMA: KEY STRATERGIES
  • TABLE 115. ALK: KEY EXECUTIVES
  • TABLE 116. ALK: COMPANY SNAPSHOT
  • TABLE 117. ALK: PRODUCT SEGMENTS
  • TABLE 118. ALK: SERVICE SEGMENTS
  • TABLE 119. ALK: PRODUCT PORTFOLIO
  • TABLE 120. ALK: KEY STRATERGIES
  • TABLE 121. AMNEAL PHARMACEUTICALS LLC.: KEY EXECUTIVES
  • TABLE 122. AMNEAL PHARMACEUTICALS LLC.: COMPANY SNAPSHOT
  • TABLE 123. AMNEAL PHARMACEUTICALS LLC.: PRODUCT SEGMENTS
  • TABLE 124. AMNEAL PHARMACEUTICALS LLC.: SERVICE SEGMENTS
  • TABLE 125. AMNEAL PHARMACEUTICALS LLC.: PRODUCT PORTFOLIO
  • TABLE 126. AMNEAL PHARMACEUTICALS LLC.: KEY STRATERGIES
  • TABLE 127. AMPHASTAR PHARMACEUTICALS, INC.: KEY EXECUTIVES
  • TABLE 128. AMPHASTAR PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
  • TABLE 129. AMPHASTAR PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
  • TABLE 130. AMPHASTAR PHARMACEUTICALS, INC.: SERVICE SEGMENTS
  • TABLE 131. AMPHASTAR PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
  • TABLE 132. AMPHASTAR PHARMACEUTICALS, INC.: KEY STRATERGIES
  • TABLE 133. GRAND PHARMA (CHINA) CO., LTD.: KEY EXECUTIVES
  • TABLE 134. GRAND PHARMA (CHINA) CO., LTD.: COMPANY SNAPSHOT
  • TABLE 135. GRAND PHARMA (CHINA) CO., LTD.: PRODUCT SEGMENTS
  • TABLE 136. GRAND PHARMA (CHINA) CO., LTD.: SERVICE SEGMENTS
  • TABLE 137. GRAND PHARMA (CHINA) CO., LTD.: PRODUCT PORTFOLIO
  • TABLE 138. GRAND PHARMA (CHINA) CO., LTD.: KEY STRATERGIES
  • TABLE 139. KALEO, INC.: KEY EXECUTIVES
  • TABLE 140. KALEO, INC.: COMPANY SNAPSHOT
  • TABLE 141. KALEO, INC.: PRODUCT SEGMENTS
  • TABLE 142. KALEO, INC.: SERVICE SEGMENTS
  • TABLE 143. KALEO, INC.: PRODUCT PORTFOLIO
  • TABLE 144. KALEO, INC.: KEY STRATERGIES
  • TABLE 145. PFIZER: KEY EXECUTIVES
  • TABLE 146. PFIZER: COMPANY SNAPSHOT
  • TABLE 147. PFIZER: PRODUCT SEGMENTS
  • TABLE 148. PFIZER: SERVICE SEGMENTS
  • TABLE 149. PFIZER: PRODUCT PORTFOLIO
  • TABLE 150. PFIZER: KEY STRATERGIES
  • TABLE 151. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY EXECUTIVES
  • TABLE 152. TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT
  • TABLE 153. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT SEGMENTS
  • TABLE 154. TEVA PHARMACEUTICAL INDUSTRIES LTD.: SERVICE SEGMENTS
  • TABLE 155. TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCT PORTFOLIO
  • TABLE 156. TEVA PHARMACEUTICAL INDUSTRIES LTD.: KEY STRATERGIES
  • TABLE 157. VIATRIS INC.: KEY EXECUTIVES
  • TABLE 158. VIATRIS INC.: COMPANY SNAPSHOT
  • TABLE 159. VIATRIS INC.: PRODUCT SEGMENTS
  • TABLE 160. VIATRIS INC.: SERVICE SEGMENTS
  • TABLE 161. VIATRIS INC.: PRODUCT PORTFOLIO
  • TABLE 162. VIATRIS INC.: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 01. EPINEPHRINE MARKET, 2022-2032
  • FIGURE 02. SEGMENTATION OF EPINEPHRINE MARKET,2022-2032
  • FIGURE 03. TOP IMPACTING FACTORS IN EPINEPHRINE MARKET
  • FIGURE 04. TOP INVESTMENT POCKETS IN EPINEPHRINE MARKET (2023-2032)
  • FIGURE 05. BARGAINING POWER OF SUPPLIERS
  • FIGURE 06. BARGAINING POWER OF BUYERS
  • FIGURE 07. THREAT OF SUBSTITUTION
  • FIGURE 08. THREAT OF SUBSTITUTION
  • FIGURE 09. COMPETITIVE RIVALRY
  • FIGURE 10. GLOBAL EPINEPHRINE MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 11. EPINEPHRINE MARKET, BY PRODUCT TYPE, 2022 AND 2032(%)
  • FIGURE 12. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR AUTO-INJECTOR, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 13. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR PREFILLED SYRINGE, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 14. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 15. EPINEPHRINE MARKET, BY APPLICATION, 2022 AND 2032(%)
  • FIGURE 16. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR ANAPHYLAXIS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 17. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR CARDIAC ARREST, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 18. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 19. EPINEPHRINE MARKET, BY DISTRIBUTION CHANNEL, 2022 AND 2032(%)
  • FIGURE 20. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 21. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 22. COMPARATIVE SHARE ANALYSIS OF EPINEPHRINE MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
  • FIGURE 23. EPINEPHRINE MARKET BY REGION, 2022 AND 2032(%)
  • FIGURE 24. U.S. EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 25. CANADA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 26. MEXICO EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 27. GERMANY EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 28. FRANCE EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 29. UK EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 30. ITALY EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 31. SPAIN EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 32. REST OF EUROPE EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 33. JAPAN EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 34. CHINA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 35. INDIA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 36. AUSTRALIA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 37. SOUTH KOREA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 38. REST OF ASIA-PACIFIC EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 39. BRAZIL EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 40. COLOMBIA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 41. ARGENTINA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 42. REST OF LA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 43. GCC EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 44. SOUTH AFRICA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 45. NORTH AFRICA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 46. REST OF MEA EPINEPHRINE MARKET, 2022-2032 ($MILLION)
  • FIGURE 47. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 48. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 49. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 50. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 51. COMPETITIVE DASHBOARD
  • FIGURE 52. COMPETITIVE HEATMAP: EPINEPHRINE MARKET
  • FIGURE 53. TOP PLAYER POSITIONING, 2022